Details for Patent: 12,053,461

« Back to Dashboard

Which drugs does patent 12,053,461 protect, and when does it expire?

Patent 12,053,461 protects KATERZIA and is included in one NDA.

This patent has seven patent family members in four countries.

Summary for Patent: 12,053,461

Title:	Amlodipine formulations
Abstract:	Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
Inventor(s):	Scott BRAUER, Gerold L. Mosher
Assignee:	Azurity Pharmaceuticals Inc
Application Number:	US17/716,505
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,053,461
Patent Claim Types: see list of patent claims	Formulation; Compound;

Drugs Protected by US Patent 12,053,461

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Azurity	KATERZIA	amlodipine benzoate	SUSPENSION;ORAL	211340-001	Jul 8, 2019		RX	Yes	Yes			Y

International Family Members for US Patent 12,053,461

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	3038989
European Patent Office	3522872
European Patent Office	3960158
European Patent Office	4585213
Spain	2886067
Spain	3035030